MSV
NBIX icon

MN Services Vermogensbeheer’s Neurocrine Biosciences NBIX Stock Holding History

MN Services Vermogensbeheer’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,000
Closed -$5.93M – 529
2023
Q4 		$5.93M Sell
45,000
-1,500
-3% -$173K 0.05% 338
2023
Q3 		$5.23M Hold
46,500
– – 0.05% 351
2023
Q2 		$4.38M Hold
46,500
– – 0.04% 391
2023
Q1 		$4.71M Hold
46,500
– – 0.05% 342
2022
Q4 		$5.55M Sell
46,500
-6,400
-12% -$750K 0.06% 323
2022
Q3 		$5.62M Sell
52,900
-3,100
-6% -$315K 0.06% 329
2022
Q2 		$5.46M Buy
+56,000
New +$5.17M 0.05% 362

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

MN Services Vermogensbeheer's NBIX Position: Q1 2024 in Review

MN Services Vermogensbeheer sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 45,000 shares — an estimated $5.93M sold.

MN Services Vermogensbeheer first reported a position in NBIX in Q2 2022 and held it in 7 quarters. The position peaked at $5.93M in Q4 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • MN Services Vermogensbeheer reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • MN Services Vermogensbeheer sold 45,000 Neurocrine Biosciences shares in Q1 2024, an estimated $5.93M.
  • MN Services Vermogensbeheer first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 7 quarters.
  • MN Services Vermogensbeheer's Neurocrine Biosciences position peaked at $5.93M in Q4 2023.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on MN Services Vermogensbeheer's 13F filing for Q1 2024, filed 29 Apr 2024.